Experimental HCV Drugs
Experimental HCV Drugs
Sofosbuvir/Ledipasvir Coformulation Cures 95% of Genotype 1 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 11 February 2014 00:00
- Written by Liz Highleyman
Between 95% and 100% of treatment-naive patients and prior non-responders with genotype 1 chronic hepatitis C achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to findings from the Phase 2 LONESTAR study published in the February 8, 2014, edition of The Lancet.
Gilead Requests FDA Approval of Sofosbuvir/ Ledipasvir Hep C Combo
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 11 February 2014 00:00
- Written by Gilead Sciences
Gilead Sciences announced this week that it has filed for U.S. Food and Drug Administration (FDA) approval of a new fixed-dose coformulation containing its recently approved HCV polymerase inhibitor sofosbuvir (Sovaldi, formerly GS-7977) plus its NS5A inhibitor ledipasvir (formerly GS-5885) for interferon-free treatment of genotype 1 chronic hepatitis C.
Daclatasvir + Asunaprevir + BMS-791325 Cures Most Genotype 1 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 28 January 2014 00:00
- Written by Liz Highleyman
An interferon-free oral combination of 3 direct-acting antiviral agents developed by Bristol-Myers Squibb led to sustained virological response in more than 90% of treatment-naive chronic hepatitis C patients with HCV genotype 1a or 1b, according to a report in the February 2014 issue of Gastroenterology.
AbbVie Oral Regimen Cures Nearly All GT1 Hepatitis C, Phase 3 Trials Now Done
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 04 February 2014 00:00
- Written by AbbVie
AbbVie announced this week that it has completed Phase 3 clinical trials of its interferon-free regimen containing 3 direct-acting antivirals, with or without ribavirin, for the treatment of chronic hepatitis C. Across all studies, between 90% and 100% of participants achieved sustained virological response, usually with 12 weeks of therapy, including hard-to-treat patient groups such as people with HCV subtype 1a and liver cirrhosis.
Boehringer Ingelheim Halts Testing of Deleobuvir Hepatitis C Regimens
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 23 January 2014 00:00
- Written by Boehringer Ingelheim
Boehringer Ingelheim will cease development of regimens containing its non-nucleoside hepatitis C virus polymerase inhibitor deleobuvir (formerly BI 207127), the company announced this week.
Web Design and Development by